Cover Image

Contemporary oncology trials, drug approvals and the physician-patient relationship

Saved in:

Bibliographic Details
Main Authors:	John-John B. Schnog (Author), Michael J. Samson (Author), Ashley J. Duits (Author)
Format:	Book
Published:	Elsevier, 2022-07-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics
by: Valentina Tateo, et al.
Published: (2023)

Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs
by: Arora A, et al.
Published: (2017)

Untoward global effects of current guideline formulation of stereotactic radiotherapy for symptomatic brain metastases by international medical societies
by: Dorien E.C.M. de Vocht, et al.
Published: (2023)

Contemporary Pediatric Hematology and Oncology
Published: (2019)

Physician recruitment of patients to non-therapeutic oncology clinical trials: ethics revisited
by: Lee eBlack, et al.
Published: (2013)

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities
by: Nidal Al‐Huniti, et al.
Published: (2020)

Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
by: Amelia D. Dahlén, et al.
Published: (2022)

Contemporary Insights into Cancer Cachexia for Oncology Nurses
by: Deborah A Boyle
Published: (2021)

Characteristics of Single Pivotal Trials Supporting Regulatory Approvals of Novel Non‐orphan, Non‐oncology Drugs in the European Union and United States from 2012−2016
by: Anne Vinther Morant, et al.
Published: (2019)

Hyponatraemia in oncology patients- what physicians should know?
by: U. Wariyapperuma
Published: (2024)

Does Industry‐Conducted All‐Case Surveillance of Newly Approved Oncology Drugs Contribute to the Revision of Package Inserts in Japan?
by: Akiyuki Suzuki, et al.
Published: (2019)

Challenges of globalization of cancer drug trials- recruitment in LMICs, approval in HICs
by: Bishal Gyawali, et al.
Published: (2022)

Oncology nursing on the move: a contemporary issue on Chinese oncology nursing in cancer care
by: Yingyang Li, et al.
Published: (2023)

Exploring the Food and Drug Administration's review and approval of Entresto (sacubitril/valsartan)
by: Ashley L. Eadie, et al.
Published: (2021)

Translatability of in vitro potency to clinical efficacious exposure: A retrospective analysis of FDA‐approved targeted small molecule oncology drugs
by: Naoki Kotani, et al.
Published: (2023)

Nurses and physicians' perception of the care of oncology patients in the emergency department
by: Silvana Bastos Cogo, et al.

Progress and challenges of confirmatory trials for cancer drugs granted conditional approval in China
by: Xingxian Luo, et al.
Published: (2024)

Clinical development time is shorter for new anticancer drugs approved via accelerated approval in the US or via conditional approval in the EU
by: Ebru Demirci, et al.
Published: (2023)

Current situation of pediatric clinical trials in China: focus on trials for drug marketing application and administrative approval
by: Lin Song, et al.
Published: (2022)

Overview of drugs approved by the FDA in 2022
by: D. V. Kurkin, et al.
Published: (2023)

New approved drugs for psoriatic arthritis
by: F.M. Perrotta, et al.
Published: (2016)

The patient-physician relationship: an account of the physician's perspective
by: Ron Berger, et al.
Published: (2020)

A Database of Drug Repurposing Clinical Trials in Oncology
by: Pan Pantziarka, et al.
Published: (2021)

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs
by: Rick A. Vreman, et al.
Published: (2022)

Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trials
by: Bingru Feng, et al.
Published: (2023)

Selected meeting abstracts of 2nd International Conference on Contemporary Oncology
by: Chouaib Salem
Published: (2024)

Comparative assessment of clinical trials, indications, pharmacokinetic parameters and side effects of approved platinum drugs
by: Stefka Ivanova
Published: (2022)

Postal survey of physicians and laboratories: Practices and perceptions of molecular oncology testing
by: Carter Ronald F, et al.
Published: (2009)

Validating patient and physician versions of the shared decision making questionnaire in oncology setting
by: Babak Nejati, et al.
Published: (2019)

An update on the novel and approved drugs for Alzheimer disease
by: Hassan Ahmad Alhazmi, et al.
Published: (2022)

Rethinking the Appraisal and Approval of Drugs for Fracture Prevention
by: Juan Erviti, et al.
Published: (2017)

Getting the Right Evidence After Drug Approval
by: Rick A. Vreman, et al.
Published: (2020)

FDA approved injection drug against schizophrenia
by: article Editorial
Published: (2023)

A review of FDA approved drugs and their formulations for the treatment of breast cancer
by: Mohini Chaurasia, et al.
Published: (2023)

Difficult medical encounters in oncology: What physicians need. An exploratory study
by: Cheryl Roumen, et al.
Published: (2023)

Relationship between contemporary art and Occuptional Therapy "Thoughts"
by: Santiso Rolán, J, et al.
Published: (2004)

Patient-reported outcome claims in European and United States orphan drug approvals
by: Szymon Jarosławski, et al.
Published: (2018)

Differences in Patient Access to Newly Approved Antibacterial Drugs in EU/EEA Countries
by: Anelia Zasheva, et al.
Published: (2024)

FDA-approved drugs in 2022: A brief outline
by: Haitham Ahmed Al-Madhagi
Published: (2023)

Drug-loaded erythrocytes: on the road toward marketing approval
by: Bourgeaux V, et al.
Published: (2016)